Informace o publikaci

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

Autoři

BRIL Vera SZCZUDLIK Andrzej VAITKUS Antanas ROZSA Csilla KOSTERA-PRUSZCZYK Anna HON Petr BEDNAŘÍK Josef TYBLOVA Michaela KOEHLER Wolfgang TOOMSOO Toomas NOWAK Richard J MOZAFFAR Tahseen FREIMER Miriam L NICOLLE Michael W MAGNUS Tim PULLEY Michael T RIVNER Michael DIMACHKIE Mazen M DISTAD B Jane PASCUZZI Robert M BABIAR Donna LIN Jiang MONTSE Querolt Coll GRIFFIN Rhonda MONDOU Elsa

Rok publikování 2023
Druh Článek v odborném periodiku
Časopis / Zdroj Neurology
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://n.neurology.org/content/100/7/e671
Doi http://dx.doi.org/10.1212/WNL.0000000000201501
Klíčová slova Myasthenia Gravis; Immunoglobulin; Corticosteroid-Sparing Effects
Popis Background and ObjectivesMyasthenia gravis (MG) is an autoimmune disease characterized by dysfunction at the neuromuscular junction. Treatment frequently includes corticosteroids (CSs) and IV immunoglobulin (IVIG). This study was conducted to determine whether immune globulin (human), 10% caprylate/chromatography purified (IGIV-C) could facilitate CS dose reduction in CS dependent patients with MG.MethodsIn this randomized double-blind placebo-controlled trial, CS-dependent patients with MG (Myasthenia Gravis Foundation of America Class II-Iva; AChR+) received a loading dose of 2 g/kg IGIV-C over 2 days (maximum 80 g/d) or placebo at week 0 (baseline). Maintenance doses (1 g/kg IGIV-C or placebo) were administered every 3 weeks through week 36. Tapering of CS was initiated at week 9 and continued through week 36 unless the patient worsened (quantitative MG score .4 points from baseline). CS doses were increased (based on the current CS dose) in patients who worsened. Patients were withdrawn if worsening failed to improve within 6 weeks or if a second CS increase was required. The primary efficacy end point (at week 39) was a .50% reduction in CS dose. Secondary and safety end points were assessed throughout the study and follow-up (weeks 42 and 45). The study results and full protocol are available at clinicaltrials.gov/ct2/show/NCT02473965. ResultsThe primary end point (.50% reduction in CS dose) showed no significant difference between the IGIV-C treatment (60.0% of patients) and placebo (63.3%). There were no significant differences for secondary end points. Safety data indicated that IGIV-C was well tolerated.DiscussionIn this study, IGIV-C was not more effective than placebo in reducing daily CS dose. These results suggest that the effects of IGIV-C and CS are not synergistic and maybe mechanistically different.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info